us stock exchange

September Corn is trading at 357 3/4, down 9 1/4 cents/bushel. December Corn is trading at 354 1/2, down 8 3/4 cents/bushel.

Corn futures have extended the session losses. Market talk about weather is constant.

The weekly corn crop condition report showed 76 percent of the crop was rated good to excellent versus 76 percent last week and 69 percent a year ago. The ten year average at this time of year is 64 percent.

Posted-In: Corn futuresFutures Commodities Markets

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

 
Related Articles Citi Says Netflix Q2 Results, Guidance Missed Even The Most Conservative Forecasts 7 Biggest Price Target Changes For Tuesday Lean Hog Futures Little Lower

us stock exchange: Yum! Brands, Inc.(YUM)

Advisors’ Opinion:

  • [By Rich Duprey]

    Yet pizza seems to be where real innovation is happening, because it’s not just Domino’s that has found success with digital technology, but Pizza Hut is alsobecoming a leader in showing just how far merchants can take artificial intelligence.The Yum! Brands (NYSE:YUM) pizza chain is still in the midst of a turnaround like the one Domino’s needed a few years back, and it is counting on technology to do it.

  • [By Daniel B. Kline]

    While its closest rivals Domino’s (NYSE:DPZ) and Papa John’s (NASDAQ:PZZA) have steadily delivered impressive growth in the United States Yum! Brands (NYSE:YUM) Pizza Hut has struggled.

  • [By WWW.GURUFOCUS.COM]

    McDonald’s is a fast-food service restaurant with more than 36 thousand restaurants in around 100 countries. With a market cap of $100 billion, the company has the largest position in the fast-food industry in the U.S., with Yum Brands (NYSE:YUM) being its closest competitor. The company sells burgers, fries and sandwiches with the vision of providing great taste, modern choices and real ingredients. McDonald’s is constantly trying to find new ways to strengthen the nutritional profile of its menu items while maintaining taste.

us stock exchange: Bayer Aktiengesellschaft (BAYRY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    A very risky Phase 3 drug for high cholesterol, anacetrapib, is listed and is in Phase 3; but several others of the class have failed, and there’s little reason to expect a success here (but you never know). Finally, a partnered heart failure drug that is also in Phase 3, vericiguat, is partnered with Bayer (OTCPK:BAYRY). This compound failed its primary endpoint in Phase 2. Yet, the partners agreed that there was hope for the highest of the three doses. Thus, I view this drug as a very high risk Phase 3 product. Maybe it will be successful and blockbuster, but it’s no sure thing.

  • [By Todd Campbell]

    Nektar Therapeutics is working with Bayer AG (NASDAQOTH:BAYRY) on an inhaledversion of Amikacin, an anti-bacterial that if successful in trials could be used alongside standard of care to treat gram-negative pneumonia in intubated and mechanically ventilated patients. If it’s eventually approved in the U.S., Nektar Therapeutics will receive a flat 30% royalty on sales. It’s also working with Bayer on an inhaled powder formulation of Cipro that could be used to treat chronic lung infections in cystic fibrosis patients. Top-line phase 3 results on both drugs should be available this year.

  • [By SEEKINGALPHA.COM]

    The Regeneron press release in November for its Q3 2017 financial and operating results reaffirmed Eylea’s full year 2017 U.S. net product sales growth of approximately 10% over 2016, which could be about $1 billion. From our model, we see the Q4 total revenues for Eylea, excluding sales outside the United States from Regeneron’s collaborative partner Bayer AG (OTCPK:BAYRY), of $1.2 billion, or a 17% increase year-on-year. REGN stock has a forward P/E ratio of 21.83 as of December 8, 2017, while the current trailing P/E is 34.57.

us stock exchange: Rigel Pharmaceuticals Inc.(RIGL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares dropped 22 percent to $2.52 after the company reported results from the second FIT Phase 3 study for fostamatinib. The company disclosed that the study did not meet primary endpoint.

us stock exchange: Royal Gold Inc.(RGLD)

Advisors’ Opinion:

  • [By Alex McGuire]

    This list ranks gold dividend stocks in the mining sector by dividend yield. And it also includes one of our top gold stock recommendations of 2017…

    Gold Dividend Stock Share Price Year-to-Date Performance Dividend Yield (as of June 30)
    DRDGOLD Ltd. (NYSE ADR: DRD) $3.19 -39.7% 10.24%
    Sibanye Gold Ltd. (NYSE ADR: SBGL) $4.70 -33.4% 5.98%
    Harmony Gold Mining Co. (NYSE ADR: HMY) $1.62 -26.7% 4.56%
    Gold Fields Limited (NYSE ADR: GFI) $3.41 +13.3% 2.73%
    Randgold Resources Ltd. (Nasdaq ADR: GOLD) $87.68 +14.9% 1.89%
    Franco Nevada Corp. (NYSE: FNV) $72.39 +21.1% 1.27%
    Royal Gold Inc. (Nasdaq: RGLD) $76.85 +21.3% 1.25%
    Eldorado Gold Corp. (NYSE: EGO) $2.58 -19.9% 1.16%
    Barrick Gold Corp. (NYSE: ABX) $15.90 -0.5% 0.75%
    Goldcorp Inc. (NYSE: GG) $13.02 -4.4% 0.62%

    Six of the 10 gold stocks listed above have posted negative returns so far in 2017. The main reason behind their losses has to do with gold price volatility.

  • [By Scott Levine]

    Climbing nearly 6% through January, the price of gold outpaced the meager gain — approximately 1% — of the S&P 500. Unsurprisingly, many of the market’s largest gold stocks enjoyed double-digit gains, including AngloGold Ashanti (NYSE:AU), Barrick Gold (NYSE:ABX), IAMGOLD (NYSE:IAG), and Royal Gold (NASDAQ:RGLD).

us stock exchange: Core Laboratories N.V.(CLB)

Advisors’ Opinion:

  • [By Craig Jones]

    Core Laboratories N.V. (NYSE: CLB) performed poorly and it is in the oil business. Cramer wouldn’t buy it, because he doesn’t want to recommend a stock in the oil and gas business.

  • [By Matthew DiLallo]

    Core Laboratories (NYSE:CLB) literally has its ear to the ground when it comes to deciphering what’s going on in the oil market. The company studies oil reservoirs, which tell it what’s happening with production, giving it a deep level of understanding on the supply side of the market. Core Labs takes what the reservoirs are saying, compares this with other data, and then blends it into an informed macro view of the oil market, which CEO David Demshur shared on the company’s recent quarterly earnings conference call. Here are five things he says the reservoirs are telling us about what’s really going on in the oil market.

  • [By Lisa Levin] Gainers
    Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) shares rose 18.4 percent to $68.65 in pre-market trading as the company reported upbeat results for its first quarter.
    Jack in the Box Inc. (NASDAQ: JACK) shares rose 9.5 percent to $111.60 in the pre-market trading session after the company posted better-than-expected earnings for its second quarter. The company also disclosed that it has retained Morgan Stanley to evaluate potential alternatives for Qdoba.
    Coherus Biosciences Inc (NASDAQ: CHRS) rose 9.8 percent to $24.20 in pre-market trading. Coherus BioSciences disclosed that it prevailed in ‘135 IPR decision.
    Qiwi PLC (NASDAQ: QIWI) rose 8.1 percent to $21.49 in pre-market trading after reporting strong quarterly results.
    Korea Electric Power Corporation (ADR) (NYSE: KEP) shares rose 7.9 percent to $20.00 in pre-market trading after dropping 4.33 percent on Tuesday
    Target Corporation (NYSE: TGT) shares rose 7.5 percent to $58.60 in pre-market trading after the company reported stronger-than-expected results for its first quarter.
    AngloGold Ashanti Limited (ADR) (NYSE: AU) rose 4.3 percent to $11.71 in pre-market trading after falling 0.09 percent on Tuesday.
    Colgate-Palmolive Company (NYSE: CL) rose 4.1 percent to $74.53 in pre-market trading after the NY Post reported that the company might be up for sale for $100 per share.
    Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 4 percent to $2.35 in pre-market trading after declining 1.74 percent on Tuesday.
    Core Laboratories N.V. (NYSE: CLB) rose 3.6 percent to $109.00 in pre-market trading after gaining 0.39 percent on Tuesday.
    Clovis Oncology Inc (NASDAQ: CLVS) rose 3.2 percent to $51.15 in pre-market trading. JP Morgan upgraded Clovis Oncology from Neutral to Overweight.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

us stock exchange: The Middleby Corporation(MIDD)

Advisors’ Opinion:

  • [By Monica Gerson]

    Middleby Corp (NASDAQ: MIDD) is expected to post its quarterly earnings at $0.84 per share on revenue of $515.56 million.

    Jack in the Box Inc. (NASDAQ: JACK) is estimated to post its quarterly earnings at $0.70 per share on revenue of $360.22 million.

Leave a Reply

Your email address will not be published. Required fields are marked *